Ketamine Tablet for Anxiety Disorders

Anxiety disorders are among the most common psychiatric conditions worldwide, yet a substantial proportion of patients do not achieve adequate relief from standard treatments — SSRIs, SNRIs, benzodiazepines, and CBT. Ketamine, particularly the oral form, is increasingly being explored as an off-label option for treatment-resistant anxiety.

The Anxiety-Ketamine Paradox

Ketamine presents an interesting paradox in anxiety treatment. At higher doses or in susceptible individuals, ketamine can induce acute anxiety, panic, or paranoia during the acute administration window. Yet emerging research suggests that at appropriate therapeutic doses, ketamine may have meaningful anxiolytic effects — both acutely and in the days to weeks following treatment.

Understanding this paradox requires distinguishing:

• Acute dissociative anxiety: Occurs during peak ketamine effects in some patients, particularly at higher doses or in those predisposed to anxiety
• Post-treatment anxiolytic effect: The reduction in anxiety symptoms observed in the days and weeks following ketamine treatment

Most of the therapeutic interest lies in the latter.

Glutamate, GABA, and Anxiety

The neurobiology connecting ketamine to anxiety relief involves glutamatergic and downstream systems:

NMDA receptor blockade in the basolateral amygdala: The amygdala is the brain's alarm center, critically involved in fear and anxiety responses. Ketamine's NMDA antagonism may reduce hyperactive amygdala responses to threat stimuli, reducing anxiety reactivity.

GABA system modulation: NMDA receptor blockade on inhibitory GABAergic interneurons can paradoxically increase net inhibitory tone in fear-processing circuits, dampening anxiety responses.

Neuroplasticity in prefrontal cortex: Ketamine-triggered BDNF release and synaptogenesis in the prefrontal cortex may restore normal top-down regulation of amygdala activity, improving emotional regulation.

Clinical Evidence by Anxiety Disorder

Generalized Anxiety Disorder (GAD)

GAD, characterized by persistent worry and physical tension, has been a focus of some ketamine research — particularly in patients with comorbid depression and anxiety.

Several studies examining ketamine for depression have incorporated anxiety measures as secondary endpoints. A consistent finding is that ketamine's antidepressant effect is frequently accompanied by anxiolytic effects, even in patients with significant GAD symptoms. In some analyses, anxiolytic effects appear more rapidly than antidepressant effects.

Feder et al. (2021) conducted a Phase 2 randomized trial of IV ketamine specifically for generalized anxiety and social anxiety disorders (without requiring comorbid depression). The results demonstrated significant reductions in anxiety compared to midazolam control, with response rates of approximately 68% vs. 36% for placebo. This was significant as a trial specifically targeting anxiety rather than treating it as a depression comorbidity.

Social Anxiety Disorder

Social anxiety disorder (SAD) was included in the Feder et al. trial described above. Patients with primary SAD who received IV ketamine showed substantial symptom reduction, with effects evident within 1 week of treatment. Ketamine tablet's application to SAD is extrapolated from IV data and small case series, with no large RCTs specific to oral formulations for this indication as of 2024.

Panic Disorder

Panic disorder treatment with ketamine is primarily supported by case reports and clinical series. The rationale includes:

• NMDA receptor involvement in panic circuit sensitization
• Ketamine's rapid anxiolytic effects potentially interrupting the panic-anticipatory anxiety cycle
• Effects on interoceptive processing (body sensation interpretation) that may reduce panic

PTSD

PTSD has substantial anxiety components and has received dedicated ketamine research attention (see our ketamine tablet for PTSD article). The distinction from "anxiety disorder" in this context is primarily categorical — many mechanisms and findings are shared.

Ketamine Tablet Specifically: Evidence and Considerations

The majority of anxiety-specific ketamine research has used IV routes. Evidence for ketamine tablet in anxiety is primarily derived from:

1. Depression-anxiety comorbidity trials: Studies of ketamine tablet for TRD that include patients with significant anxiety and report secondary anxiety outcomes
2. Case series: Clinical reports from practices using ketamine tablet for TRD patients with prominent anxiety
3. Pharmacological extrapolation: Assuming ketamine tablet's anxiolytic potential follows from the same mechanisms as IV

Ketamine Tablet Advantages for Anxiety Patients

Paradoxically, the lower bioavailability of ketamine tablet may be advantageous for anxiety patients:

• Lower peak plasma levels reduce the risk of acute anxiety or dissociation during administration
• Slower onset gives patients time to adjust to effects gradually
• At-home administration avoids the clinical environment that some anxious patients find distressing
• Gentler experiential profile may be better tolerated by anxiety-prone individuals

Ketamine Tablet Risks for Anxiety Patients

The primary risk is that even at lower oral doses, some anxiety-prone patients experience:

• Acute anxiety during the peak of ketamine effects
• Worsening of health anxiety due to awareness of cardiovascular effects (heart rate elevation)
• Panic-like responses to dissociation

For these patients, very low starting doses, careful titration, appropriate psychological preparation, and possibly co-prescription of a low-dose benzodiazepine (e.g., lorazepam 0.5 mg) for acute anxiety management during sessions may be needed.

Dosing Considerations for Anxiety

Doses for anxiety treatment follow similar protocols to depression:

Daily low-dose maintenance: 50–200 mg/day for chronic anxiolytic effects without acute sessions. Particularly useful for GAD where continuous symptom control is needed.

Structured sessions: 200–400 mg per session for more pronounced effect; lower doses than might be used for severe TRD to minimize acute anxiety risk.

Starting at lower doses than in depression protocols and titrating more slowly is generally prudent for anxiety patients.

Combination Treatments

For anxiety patients, ketamine tablet is most commonly used as:

1. Augmentation of ongoing SSRI/SNRI therapy: Continuing the baseline anxiolytic medication while adding ketamine
2. Bridge during medication changes: Providing rapid anxiolytic coverage while a new medication reaches therapeutic levels
3. Integrated with psychotherapy: Ketamine's window of enhanced neuroplasticity may facilitate anxiety-focused CBT, exposure therapy, or EMDR

What to Tell Your Prescriber

If you are considering ketamine tablet for anxiety, discuss:

• Your history with anxiety triggers, including any prior medication-induced anxiety
• Whether you have experienced anxiety or panic attacks previously with any dissociative substances or anesthetics
• The severity of your anxiety relative to any co-occurring depression
• Your comfort with at-home vs. supervised administration
• Whether you have a therapist who could provide integration support

Anxiety disorders represent one of the most promising emerging frontiers for ketamine tablet therapy, though the evidence base is less mature than for TRD. Careful patient selection and monitoring are essential.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches